120 patients which is about 10% of CFers in Ireland. At E240k each, that's....$28m, plus about the same in England...probably similar in France/Germany.....other countries to come....and remember this, is a small fraction of the total CF population......yawn at that. Just be happy that this is saving lives and you'll still make money if you are long on this.
yeah at 234K euros for a year supply. why so expensive? the molecule isn't that outrageous. wonder how many steps to make it? I know vrtx wants a profit but I guess since there aren't many CF patients in the world (like diabetes or high cholesterol), they have to gouge the heck out of patients and medical insurance.
"yeah at 234K euros for a year supply. why so expensive? the molecule isn't that outrageous. wonder how many steps to make it? "
Drug pricing is not based on the cost of production. It is based on the cost of researching/developing the drug from pre-clinical stage though phase III, the marketing cost, and most important, the size of the population it will serve -- the smaller the size, the higher the cost and that is the reason also for drug orphan designation.